Autolus Therapeutics plc American Depositary Share Share Price
NASDAQ: AUTL | Small CapAutolus Therapeutics plc American Depositary Share Stock Performance
Open $2.06 | Prev. Close $2.02 | Circuit Range N/A |
Day Range $2.03 - $2.13 | Year Range $1.18 - $2.52 | Volume 1,25,785 |
Average Traded $2.08 |
Autolus Therapeutics plc American Depositary Share Share Price Today
As of 10 August 2026, Autolus Therapeutics plc American Depositary Share's share price is $2.10. The stock opened at $2.06, compared to its previous close of $2.02. During today's trading session, Autolus Therapeutics plc American Depositary Share's share price traded between $2.03 and $2.13, with an average price of $2.08. Over the past 52 weeks, the stock has recorded a high of $2.52 and a low of $1.18. In terms of performance, Autolus Therapeutics plc American Depositary Share's share price has risen by 23.10% over the last six months and is up 40.33% on a year-on-year basis.
Autolus Therapeutics plc American Depositary Share Share Price Chart
Autolus Therapeutics plc American Depositary Share Stock Fundamentals & Key Indicators
Market Cap $560.22M | PE Ratio (TTM) -1.95 | Dividend Yield N/A |
EPS (TTM) $-1.08 | Revenue (TTM) $75.39M | Return On Equity (TTM) -161.42% |
Profit Margin -381.40% | Debt to Equity 0.41 | Quarterly Earnings Growth YoY 3.63% |
Autolus Therapeutics plc American Depositary Share Quarterly Profit & Loss
All figures in USD
Autolus Therapeutics plc American Depositary Share Annual Profit & Loss
All figures in USD
About Autolus Therapeutics plc American Depositary Share
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics plc American Depositary Share Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.72 | $2.11 | +40.67% |
Jul 2026 | $1.58 | $1.50 | -5.96% |
Jun 2026 | $1.85 | $1.59 | -15.16% |
May 2026 | $1.41 | $1.88 | +32.39% |
Apr 2026 | $1.42 | $1.42 | +2.90% |
Mar 2026 | $1.64 | $1.38 | -19.30% |
Feb 2026 | $1.37 | $1.71 | +24.82% |
Jan 2026 | $1.94 | $1.37 | -30.81% |
Dec 2025 | $1.35 | $1.98 | +39.93% |
Nov 2025 | $1.57 | $1.42 | -9.29% |
Oct 2025 | $1.64 | $1.56 | -4.00% |
Sep 2025 | $1.47 | $1.63 | +8.33% |
AUTL Share Price FAQs
What is Autolus Therapeutics plc American Depositary Share share price today?
What is the 52 week high and 52 week low of Autolus Therapeutics plc American Depositary Share stock?
What is AUTL's market capitalisation today?
What is AUTL's net income for the last quarter?
What is the 5 year returns of AUTL?
What is the high & low stock price of AUTL today?
Can I buy AUTL shares in India?